Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Nov 5;16(22):3722.
doi: 10.3390/cancers16223722.

Measurable Residual Disease in Hematological Cancers

Krzysztof Jamroziak  1 , Bartosz Puła  2
Affiliations
Editorial

Measurable Residual Disease in Hematological Cancers

Krzysztof Jamroziak et al. Cancers (Basel). .

Abstract

Minimal residual disease (MRD) is most easily defined as a minimal amount of cancer cells that remain following the treatment of the disease, potentially owing to disease recurrence and the patient's dismal prognosis [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Chen J., Gale R.P., Hu Y., Yan W., Wang T., Zhang W. Measurable residual disease (MRD)-testing in haematological and solid cancers. Leukemia. 2024;38:1202–1212. doi: 10.1038/s41375-024-02252-4. - DOI - PMC - PubMed
    1. Moritz J., Schwab A., Reinisch A., Zebisch A., Sill H., Wölfler A. Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions. Biomedicines. 2024;12:599. doi: 10.3390/biomedicines12030599. - DOI - PMC - PubMed
    1. Zuna J., Hovorkova L., Krotka J., Koehrmann A., Bardini M., Winkowska L., Fronkova E., Alten J., Koehler R., Eckert C., et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: Different significance in typical ALL and in CML-like disease. Leukemia. 2022;36:2793–2801. doi: 10.1038/s41375-022-01668-0. - DOI - PubMed
    1. Anderson K.C., Auclair D., Adam S.J., Agarwal A., Anderson M., Avet-Loiseau H., Bustoros M., Chapman J., Connors D.E., Dash A., et al. Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin. Cancer Res. 2021;27:5195–5212. doi: 10.1158/1078-0432.CCR-21-1059. - DOI - PMC - PubMed
    1. Döhner H., Wei A.H., Appelbaum F.R., Craddock C., DiNardo C.D., Dombret H., Ebert B.L., Fenaux P., Godley L.A., Hasserjian R.P., et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–1377. doi: 10.1182/blood.2022016867. - DOI - PubMed

Publication types

LinkOut - more resources